First new antibiotic in 50 years could help treat superbug labelled ‘urgent threat'
Yesterday, Roche, the Swiss pharmaceutical giant, announced it will take zosurabalpin into the third and last phase of testing on humans.
It is the first drug in five decades to show promise of tackling Acinetobacter baumannii, a pathogen which is described as a 'priority' by the World Health Organisation and an 'urgent threat' by the Centres for Disease Control and Prevention, the US national public health agency.
The drug-resistant bacteria disproportionately impact patients who are in the hospital, causing infections such as pneumonia and sepsis.
It is estimated that between 40pc and 60pc of infected patients, many of whom are immunocompromised because of conditions such as cancer, die as a result of the bug.
One of the reasons it is so difficult to treat is that it has a double-walled 'membrane' protecting it from attack, so it is difficult to get drugs into it and to keep them in, experts said.
Zosurabalpin, which has been developed alongside researchers at Harvard University, targets the 'machine' which stops the outer membrane from forming properly. It works differently to all existing antibiotics and it is hoped that it could lay the foundations for future drugs.
'Our goal is to contribute new innovations to overcome antimicrobial resistance, one of the biggest infectious disease challenges to public health,' Michael Lobritz, global head infectious diseases at Roche, said.
The phase-three trial, which it is hoped will start later this year or in early 2026, will look at around 400 patients with a carbapenem-resistant Acinetobacter Baumannii (Crab) infection who will either receive zosurabalpin or the current standard of care.
It is hoped that the drug will be approved by the end of the decade.
Pharmaceutical companies have in the past been unwilling to pursue new antibiotics because of a difficult market in which the drugs are used sparingly to try and avoid resistance.
However, the UN has warned that if nothing is done to address the issue, drug-resistant diseases could cause 10 million deaths each year by 2050.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Extra.ie
4 hours ago
- Extra.ie
Irish family shocked by message from assisted dying clinic
An Irish family has been left reeling after allegedly receiving a text message from a suicide clinic in Switzerland informing them that their mother was dead, and her ashes would be arriving in the post. 58-year-old Maureen Slough, based in Co Cavan, travelled to the Pegasos clinic on July 8, telling her family she was going to Lithuania with a friend, according to the Irish Independent. However, the woman's daughter, Megan, says she was shocked when she received a WhatsApp message saying her mother had died listening to gospel music sung by Elvis Presley, while her family believed she was holidaying in Lithuania. Maureen Slough, a 58-year-old mother from Cavan who reportedly took her own life at the Pegasos clinic, and her daughter Megan Royal. Pic: Facebook Now her family is demanding answers to find out why their mother, who they say attempted suicide a year earlier following the deaths of her two sisters, was able to seek assisted dying without the family being informed. Her daughter Megan told the Irish Independent that she had to track her mother's ashes through the postal system. It's reported that after the shock of finding out Ms Slough had travelled alone to Switzerland and paid a reported £13,000 to the Pegasos Swiss Association to facilitate her death two days later, the family began investigating how this could have happened They were shocked to find that Pegasos accepted their mother's application, considering her long history of mental illness, and claimed the clinic did not inform the family of her plan. Ms Slough allegedly travelled alone to Switzerland and paid £13,000 to the Pegasos Swiss Association to facilitate her death two days later. Pic: Facebook But the Pegasos group has allegedly said that it received a letter from Ms Slough's daughter, Megan, saying she was aware of her mother's desire to die and that she had accepted her decision, something Megan has denied. The clinic also claimed it verified the authenticity of the letter through an email response to Ms Royal, using an email address supplied by her mother, but Megan insists she never wrote such a letter or verified any contact from the clinic, and the family claim their mother may have forged the letter and then verified it using an email address she created herself. This is not the first time the non-profit assisted dying clinic Pegasos has attracted controversy. Alistair Hamilton with his mother Judith. Pic: ITV In 2023, Alistair Hamilton, a 47-year-old teacher from the UK, with no diagnosed illness, took his own life at the Swiss clinic, without the knowledge of his family, and after that case, Pegasos reportedly promised it would always contact a person's relatives before carrying out assisted death. His mother, Judith, later visited the clinic where her son had died to look for answers. Since 1942, under Swiss Law, people have been allowed to help others to die, as long as their motives are not for personal gain, such as an inheritance or other form of monetary gain. The law states that the person wishing to die must be of sound mind, but they do not need to be terminally ill or have any medical conditions. The country's assisted suicide clinics are non-profit organisations. Earlier this year, British MPs voted to change the suicide law in the UK and allow terminally ill people in England and Wales the choice to end their lives.
RTÉ News
4 hours ago
- RTÉ News
Sanofi sees 'manageable' impact from US tariffs, expects strong growth
Drugmaker Sanofi said today it believes the impact from US tariffs to be manageable as it raised its sales growth expectations for the year, banking on expanded demand for its anti-inflammatory drug Dupixent to treat more conditions. The French firm now expects annual sales growth in the high single-digits at constant currency rates, compared to a previous forecast of mid to high-single-digit growth. Sanofi's shares fell nearly 4%, however, as it reported lower than expected earnings for the quarter on higher research costs, though it maintained its earnings growth expectations for the year. European drugmakers are currently weighing their future prospects in the US, the world's biggest pharmaceuticals market, in light of the trade deal struck between Brussels and Washington this week. "Under the scenarios being discussed including the possibility of a 15% rate on imports from the European Union, we currently view the potential impact on Sanofi as manageable," said Chief Financial Officer François-Xavier Roger. The US has also been conducting a national security investigation into the pharmaceutical sector that could result in separate sectoral tariffs. "It's still too early to draw firm conclusions," Roger said on a call with journalists. Sanofi was also in discussions with the US government about drug pricing, he said, after President Donald Trump issued an executive order in May directing drugmakers to lower US prices to align with what other countries pay. Selling medicines directly to patients, for example, could reduce US prices, Roger said, as it would cut out pharmacy benefit managers that act as middlemen between drugmakers and consumers. "Direct sales to patients. That's something that we may consider," he said. Swiss firm Roche said last week it was considering selling its prescription medicines directly to US patients as part of talks with Washington. Sanofi has significantly ramped up investments in research and development, and plans to be more active with acquisitions as it looks to build its next wave of products. Investor hopes, meanwhile, remain high for Dupixent - the company's main growth driver used to treat conditions including asthma and eczema - particularly since it gained US approval last year to treat chronic obstructive pulmonary disease, a common lung condition. Sales of Dupixent, which Sanofi makes with partner Regeneron, rose 21.1% to €3.83 billion, compared to €3.74 billion expected on average by analysts in a company-provided poll. Roger said that outside of the US, Dupixent sales exceeded €1 billion, despite some price decreases in China. The drugmaker confirmed that it expects earnings to grow by a low double-digit percentage this year, but said the forecast now includes all expenses from its newly acquired businesses. Quarterly business operating income came in at €2.46 billion, below the average analyst estimate of €2.57 billion. Sanofi said greater profit sharing with Regeneron also weighed on its earnings.
Irish Independent
11 hours ago
- Irish Independent
The Indo Daily: How a WhatsApp message told an Irish family that their mother had died by assisted suicide
That's the harsh reality facing her family and friends. Maureen's daughter Megan Royal talks of her mother's mental well-being and her trip to a Swiss clinic where she made the decision to die by assisted suicide. But why were her relatives kept out of the loop? Today on the Indo Daily Kevin Doyle is joined by Megan, who will tell us about her mother's secret journey to the Pegasus Clinic in Switzerland, and by Conor Feehan, senior journalist with the Irish Independent, who has been looking into such clinics and asking questions about the safeguards in place.
